Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group

Acta Oncologica

Volumn 47, Issue 2, 2008, Pages 239-247

  Madsen, Anders Husted ^a   Jensen, Anni Ravnsbaek ^a   Christiansen, Peer ^a   Garne, Jens Peter ^c   Cold, Soeren ^b   Ewertz, Marianne ^c   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; DENMARK; EARLY DIAGNOSIS; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; DENMARK; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; REGISTRIES; SENTINEL LYMPH NODE BIOPSY; TIME FACTORS;

EID: 38349169021     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701727436     Document Type: Article

References (34)

1. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999;17:2334-40.
2. Lauridsen MC, Garne JP, Sorensen FB, Melsen F, Lernevall A, Christiansen P, et al. Sentinel lymph node biopsy in breast cancer-experience with the combined use of dye and radioactive tracer at Aarhus University Hospital. Acta Oncol 2004;43:20-26.
3. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138-42.
4. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer. N Engl J Med 2003;349:546-53.
5. Swenson KK, Mahipal A, Nissen MJ, Tuttle TM, Heaton K, Lally RM, et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer 2005;104:1834-9.
6. Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 2006;93:129-32.
7. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-9.
8. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A metaanalysis. Cancer 2006;106:4-16.
9. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
10. Kuijt GP, Voogd AC, van de Poll-Franse LV, Scheijmans LJ, van Beek MW, Roumen RM. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients. Eur J Surg Oncol 2005;31:500-5.
11. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001;92:1378-84.
12. Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005;241:319-25.
13. Galimberti V. International Breast Cancer Study Group Trial of Sentinel Node Biopsy. J Clin Oncol 2006;24:210-1.
14. Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984;49:709-15.
15. Jensen AR. A comparative population based study on breast cancer patients in Denmark and Sweden-Aspects of early diagnosis, axillary surgery and registration. 2002. Faculty of Health Sciences, University of Aarhus.
16. Jensen AR, Garne JP, Storm HH, Engholm G, Moller T, Overgaard J. Does stage at diagnosis explain the difference in survival after breast cancer in Denmark and Sweden? Acta Oncol 2004;43:719-26.
17. van der Heiden-van der Loo, Bezemer PD, Hennipman A, Siesling S, van Diest PJ, Bongers V, et al. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 2006;32:710-14.
18. Vanderveen KA, Schneider PD, Khatri VP, Goodnight JE, Bold RJ. Upstaging and Improved Survival of Early Breast Cancer Patients after Implementation of Sentinel Node Biopsy for Axillary Staging. Ann Surg Oncol 2006.
19. Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002;11:359-64.
20. Jensen AR, Storm HH, Moller S, Overgaard J. Validity and representativity in the Danish Breast Cancer Cooperative Group - a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol 2003;42:179-85.
21. Rostgaard K, Holst H, Mouridsen HT, Lynge E. Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark. Cancer Causes Control 2000;11:669-74.
22. Key Indicators. Statistics Denmark www.dst.dk. 2006.
23. DBCG. Guidelines from the Danish Breast Cancer Cooperative Group. www.dbcg.dk. 2006.
24. Flemming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP, et al. "AJJC Cancer Staging Manual." Lippincott - Raven, 1997.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
26. Galimberti V, Veronesi P, Arnone P, De CC, Renne G, Intrntra M, et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol 2002;9:924-8.
27. Tjan-Heijnen VC, Buit P, de Widt-Evert LM, Ruers TJ, Beex LV. Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 2001;70:81-8.
28. Feinstein AR, Sosin DA, Wells CK. The Will Rogers Phenomenon: Improved technologic diagnosis and stage migration as a source of nontherapeutic improvement in cancer prognosis. Transactions of the Association of American Physicians 1984;97:19-24.
29. Weaver DL. Pathological evaluation of sentinel lymph nodes in breast cancer: a practical academic perspective from America. Histopathology 2005;46:702-6.
30. van Rijk MC, Deurloo EE, Nieweg OE, Gilhuijs KG, Petersen JL, Rutgers EJ, et al. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 2006;13:31-5.
31. Cancer incidence in Denmark 2001. National Board of Health 2006; Copenhagen.
32. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 2006;119:2417-22.
33. Saha S, Farrar WB, Young DC, Ferrara JJ, Burak WE. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000;73:134-7.
34. Grabau DA, Jensen MB, Blichert-Toft M, Andersen JA, Dyreborg U, Carstensen B, et al. The importance of surgery and accurate axillary staging for survival in breast cancer. European Journal of Surgical Oncology 1998;24:499-507.